Michael Barbella, Managing Editor03.15.24
ZOLL has received U.S. Food and Drug Administration clearance and CE mark* for a significant upgrade to the versatility of itse Thermogard Temperature Management System.
The Thermogard System is now the first and only system to offer the versatility of both core and surface-based temperature management treatment options. The single, streamlined platform now offers solutions for personalized patient care with precise temperature control and intelligent analytics.
“Thermogard with both catheter-based and pad options supports our mission to improve patient outcomes and help save lives,” ZOLL Circulation President Christopher Barnabas said. “ZOLL’s Thermogard platform is now the only all-in-one temperature management technology. This one-of-a-kind solution delivers high-quality patient care while supporting hospitals’ evolving treatment protocols and decreasing the workload for nursing staff.”
*The Surface pads and the Surface Start-Up Kit is a self-certified medical device.
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides technologies that help clinicians, EMS, fire professionals, and lay rescuers improve patient outcomes in critical cardiopulmonary conditions.
The Asahi Kasei Group was founded in 1922 and has consistently grown through the transformation of its business portfolio to meet evolving needs. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors: Material, Homes, and Health Care. Its healthcare operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and biotherapeutics manufacturing, as well as pharmaceuticals and diagnostic reagents. Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050.
The Thermogard System is now the first and only system to offer the versatility of both core and surface-based temperature management treatment options. The single, streamlined platform now offers solutions for personalized patient care with precise temperature control and intelligent analytics.
“Thermogard with both catheter-based and pad options supports our mission to improve patient outcomes and help save lives,” ZOLL Circulation President Christopher Barnabas said. “ZOLL’s Thermogard platform is now the only all-in-one temperature management technology. This one-of-a-kind solution delivers high-quality patient care while supporting hospitals’ evolving treatment protocols and decreasing the workload for nursing staff.”
*The Surface pads and the Surface Start-Up Kit is a self-certified medical device.
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides technologies that help clinicians, EMS, fire professionals, and lay rescuers improve patient outcomes in critical cardiopulmonary conditions.
The Asahi Kasei Group was founded in 1922 and has consistently grown through the transformation of its business portfolio to meet evolving needs. With more than 48,000 employees worldwide, the company contributes to a sustainable society by providing solutions to the world's challenges through its three business sectors: Material, Homes, and Health Care. Its healthcare operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, and biotherapeutics manufacturing, as well as pharmaceuticals and diagnostic reagents. Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050.